ID   SNU-484 Ola-R
AC   CVCL_C1NA
SY   SNU-484/olaparib-resistant; Olaparib-resistant SNU-484
DR   cancercelllines; CVCL_C1NA
DR   Wikidata; Q114313041
RX   PubMed=32028591;
CC   Population: Korean.
CC   Selected for resistance to: ChEBI; CHEBI:83766; Olaparib.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Stomach; UBERON=UBERON_0000945.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0100 ! SNU-484
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=32028591; DOI=10.3390/cancers12020334; PMCID=PMC7072281;
RA   Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H.,
RA   Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.;
RT   "TDP1 and TOP1 modulation in olaparib-resistant cancer determines the
RT   efficacy of subsequent chemotherapy.";
RL   Cancers (Basel) 12:334.1-334.17(2020).
//